Sucampo Pharmaceuticals - Articles and news items

FDA grants fast track designation to Sucampo’s cobiprostone for oral mucositis

Industry news / 8 May 2015 / Victoria White

The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...